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Abstract. The interactions of integrins with extraceUu- 
lar matrix proteins can activate focal adhesion kinase 
(FAK) and suppress apoptosis in normal epithelial and 
endothelial cells; this subset of apoptosis has been 
termed "anoikis." Here, we demonstrate that FAK 
plays a role in the suppression of anoikis. Constitutively 
activated forms of FAK rescued two established epithe- 
lial cell lines from anoikis. Both the major autophos- 
phorylation site (Y397) and a site critical to the kinase 
activity (K454) of FAK were required for this effect. 
Activated FAK also transformed MDCK cells, by the 
criteria of anchorage-independent growth and tumor 
formation in nude mice. We provide evidence that this 
transformation resulted primarily from the cells' resis- 
tance to anoikis rather than from the activation of 
growth factor response pathways. These results indicate 
that FAK can regulate anoikis and that the conferral of 
anoikis resistance may suffice to transform certain epi- 
thelial cells. 
I 
N  normal  epithelial  (Frisch  and  Francis,  1994; Bou- 
dreau et  al.,  1995)  and endothelial (Meredith et  al., 
1993; Brooks et al., 1994) cells, signaling by the appro- 
priate liganded integrins suppresses a subset of apoptosis 
known as "anoikis" (for review see Ruoslahti and Reed, 
1994).  Anoikis is physiologically important in controlling 
the cell number in the skin (Polakowska et al., 1994) and 
digestive tract (Hall et al., 1994), as well as morphogenesis 
of the mammary gland (Boudreau et al., 1995) and devel- 
oping  mouse  embryo  (Coucouvanis  and  Martin,  1995). 
With the advent of anoikis, epithelial anchorage depen- 
dence is also being reexamined in terms of the connections 
between integrin signaling and the apoptotic machinery. 
In principle, the acquisition of anoikis resistance could fa- 
cilitate anchorage-independent growth and perhaps trans- 
formation. Different integrin heterodimers may differ in 
their  ability to  suppress  apoptosis  in  a  given  cell  type 
(Boudreau et al.,  1995; Zhang et al., 1995).  Tumor cells 
perhaps could gain anchorage independence in a specific 
environment by expressing an anoikis-suppressing integrin 
type (Juliano and Varner, 1993). 
Malignant transformation of cells by activated forms of 
ras or src is accompanied by a conversion to anoikis resis- 
tance (Frisch and Francis, 1994). The causal relationships 
between  anoikis  resistance  and  transformation are  cur- 
rently unknown and cannot be  studied with such onco- 
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genes because they also perturb growth factor pathways. 
Integrin-matrix interactions lead to the autophosphoryla- 
tion of the tyrosine kinase, FAK,  1 which is thought to act 
as  an  integrin  signal  transducer.  FAK  interacts  with  a 
number of cellular proteins, including c-src,  grb2, phos- 
phatidylinositol-3-kinase, paxillin, and p130 caS (SchaUer and 
Parsons, 1994, 1995; Schlaepfer et al., 1994; Polte and Hanks, 
1995; Richardson and Parsons, 1995).  Importantly, while 
cell-matrix interactions facilitate mitogenic signaling by 
growth factors (for review see Schwartz and Ingber, 1994), 
these interactions might not be expected to be mitogenic 
by themselves. The current understanding of FAK sup- 
ports this idea. For example, although FAK interacts with 
grb2 and c-src, cell-matrix interactions have not been shown 
to activate either ras-GTP-binding activity or src-kinase 
activity. In fact, the  SH2  domain of c-src interacts with 
FAK and actually promotes cell-matrix interactions (Kap- 
lan et al., 1995). 
In  light of these  properties,  the  possibility that FAK 
might control anoikis was tested in this study. We used a 
form of FAK that had been activated by membrane target- 
ing. The expression of activated FAK conferred resistance 
to anoikis, which sufficed to transform MDCK cells. 
Materials and Methods 
Antibodies and Immunologic Detection Methods 
For immunofluorescence,  cells were fixed in 2% formaldehyde for 10 min, 
1. Abbreviations used in this paper: FAK, focal adhesion kinase; MPB, my- 
elin basin protein. 
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tibodies, followed by FITC-labeled  goat  anti-mouse (1:100;  Boeringer 
Mannheim Biochemicals, Indianapolis, IN), and photographed using a mi- 
croscope (Axiovert; Carl Zeiss, Inc., Thornwood, NY)  (final magnifica- 
tion, 450). 
For experiments comparing phosphorylated proteins in  attached vs. 
suspended cells, MDCK  cells expressing CD2-FAK  (wild-type), CD2- 
FAK(454*), or CD2-FAK(397*) were detached by trypsinization followed 
by washing with DME/10% FCS and DME/0.5% BSA. Cells were then 
either  washed  once  with  PBS  and  lysed  in  modified  RIPA  buffer 
(Schlaepfer et al., 1994) ("suspended cells"), or plated on type I collagen 
(20 i~g/ml)-coated dishes for 40 min at 37°C and lysed in modified RIPA 
buffer ("adherent cells"). Antibodies were added to lysates containing 
equal amount of protein, and samples were rotated at 4°C for 1 h. Gam- 
mabind Sepharose (Pharmacia, Uppsala, Sweden) was added to the ly- 
sates to precipitate the  antibody-antigen complexes, and  rotation was 
continued for 2 h. The immunoprecipitates were then washed three times 
in wash buffer (RIPA buffer without SDS or deoxycholate), resuspended 
in SDS-PAGE sample buffer, boiled, electrophoresed on 4--12% Precast 
SDS-PAGE gels (NOVEX, Encinitas, CA), and electrophoretically blot- 
ted onto Immobilon-PVDF membranes. The blots were reacted with pri- 
mary antibodies as indicated followed by HRP-labeled anti-mouse (Bio- 
Rad Laboratories, Hercules, CA), and visualized by enhanced chemilumi- 
nescent detection (Amersham Corp., Arlington Heights, IL). 
For analysis of MAP kinase activation, MDCK cells, MDCK cells ex- 
pressing CD2-FAK (wild-type), and rat embryonic fibroblast (REF-52) 
cells were serum starved in DME/0.5.%  FCS for 18 h and detached by 
trypsinization followed by washing with DME/0.5% FCS and DME/0.5% 
BSA. Cells were then either immediately lysed in modified RIPA buffer 
(time zero), or kept in suspension or plated on type I collagen (20 ~g/ml)- 
coated dishes at 37°C for 15-120 min and lysed in modified RIPA buffer. 
Cells stimulated with 800 nM PMA for 15 rain were used as a positive con- 
trol for MAPK activation. MAP kinase activity was assayed essentially as 
described (Chen et al., 1994). Briefly, MAP kinases were immunoprecipi- 
rated from total cell lysates (200 i.tg/sample)  with polyclonal anti-MAP ki- 
nase  antibody C-16  (Santa  Cruz Biotechnology, Santa  Cruz,  CA)  and 
Gammabind Sepharose as described above. The immunoprecipitates were 
washed twice with 250 mM Tris, pH 7.5, and once with 100 mM NaC1, 50 
mM Hepes, pH 8.0. The immunoprecipitated MAP kinases were incu- 
bated in a mixture containing 1 I~Ci of [~/-32p]ATP, 50 IxM ATP, 10 mM 
MgC12,  1 mM DT]?,  1 mM benzamine, 0.3 mg/ml myelin basic protein 
(MBP; Life Technologies, Inc., Grand Island, NY) and 25 mM Hepes, pH 
8.0, at 30°C for 20 rain. The samples were electrophoresed on a 15% poly- 
acrylamide gel. After staining with Coomassie brilliant blue, the gel was 
dried and analyzed by autoradiography. Quantitative analysis of the MBP 
bands was carried out by using the Bio-Rad GS Phosphorlmager. Equal 
immunoprecipitation and loading of MAP kinases was assessed by immu- 
noblotting samples of immunoprecipitated MAP kinases with a  mono- 
clonal anti-MAP kinase antibody (clone B3B9). 
Antibodies were  obtained  from  the  following sources:  CD2:  clone 
RPA2.10 (PharMingen, San Diego, CA); CD8: clone 2.43 (Sarmiento et 
al., 1980; gift of B. Buehler, Burnham Institute); src: clone 237 (obtained 
from Dr. Joan Brugge, Ariad Pharmaceuticals) and v-src Ab-1 (Oncogene 
Science Inc., Manhasset, NY); MAPK: clone B3B9  (obtained from M. 
Weber,  University  of  Virginia);  phosphotyrosine: Py20  (Transduction 
Laboratories, Lexington, KY); FAK: clone 77  (Transduction Laborato- 
ries);  paxillin:  clone  349  (Transduction  Laboratories);  vinculin:  (poly- 
clonal; Sigma Chemical Co., St. Louis, MO). 
Plasmids 
The CD2-FAK (wild-type), CD2-FAK (397* or 454*),  or CD2 plasmids 
were described previously (Chanet al., 1994). CD8-FAK was constructed 
by fusing the Nco-BamHI fragment containing the ectodomain and trans- 
membrane domain of mouse CD8  (from pLVLy2-Hy; Nakauchi  et al., 
1987), with the Clal-EagI fragment containing the FAK coding sequence 
using an oligonucleotide adaptor to adjust the reading frame. 
Anoikis Assays 
Assays for internucleosomal DNA cleavage were performed as described 
previously (Frisch and Francis, 1994).  Briefly, cell lines were grown to 
confluence, trypsinized, and 3 × 106 ceils were suspended on polyhydroxy- 
ethylmethacrylate-coated dishes for 7 h; low tool wt DNA was analyzed 
on a  1.4%  agarose gel after normalizing loading vol against the corre- 
sponding total cellular protein (using Bio-Rad protein assay). Results are 
representative of 2-3 repetitions. For flow cytometric analysis, cells were 
fixed in 70% ethanol and stained with 20 p,g/ml propidium iodide in the 
presence of 5 p,g/ml RNase before flow cytometry on a FACscan (Becton 
Dickinson, Mountain View, CA) and the percentages of cells in apoptosis 
were determined using the DNAquest program. 
Results 
Expression and Localization  of CD2-FAK 
A chimeric protein created by the fusion of the CD2 anti- 
gen ectodomain to full-length FAK activates FAK such 
that it retains tyrosine 397 autophosphorylation and full 
tyrosine kinase  activity in  suspended  cells  (Chan  et  al., 
1994).  MDCK cells or the immortalized keratinocyte cell 
line  HaCat  were  transfected  with  expression  plasmids 
bearing  the  CD2-FAK  chimeras  in  which  the  FAK  se- 
quences were wild-type or mutated to disable the src-SH2 
target sequence (Y397F) or the kinase activity (K454R). 
Western blotting of the cell lines revealed expressed pro- 
teins of the predicted molecular weights that were reactive 
with anti-CD2 antibodies (Fig. 1 A). Western blotting with 
anti-FAK antibodies indicated that less CD2-FAK was ex- 
pressed than endogenous FAK (Fig. 1 A). 
Immunofluorescence analysis showed punctate, pericy- 
toplasmic localization of CD2-FAK in MDCK and HaCat 
cells (Fig. 1 B). Because focal contacts of these cell lines 
were  not  well-formed  under  these  experimental  condi- 
tions,  localization of CD2-FAK  to  these  structures  was 
confirmed in rat embryo fibroblasts that were transiently 
transfected with the CD2-FAK (wild-type or mutant) ex- 
pression constructs (Fig. 1 B). The CD2 ectodomain pro- 
tein expressed alone localized diffusely over the entire cell. 
CD2-FAK Is Constitutively  Activated in MDCK Cells 
In  contrast  with  wild-type  FAK,  CD2-FAK,  expressed 
transiently in transfected COS cells, remains active in sus- 
pended cells (Chan et al.,  1994). We used this property of 
CD2-FAK to examine the cellular effects of FAK activation. 
First, we performed several experiments to determine 
whether CD2-FAK behaved as a constitutively activated 
FAK in MDCK cells. Tyrosine phosphorylation of the en- 
dogenous FAK was undetectable in suspended cells and 
increased rapidly in cells adhering to collagen (Fig. 2, top). 
This occurred whether the coexpressed CD2 -FAK was in 
its wild-type or mutated  form. However, the  CD2-FAK 
(wild-type) was highly phosphorylated in suspended cells, 
and  even  more  phosphorylated  in  attached  cells.  This 
phosphorylation was  abolished  by mutation  of tyrosine 
397 and dramatically reduced by mutation of lysine 454. 
The levels of the FAK or CD2-FAK proteins themselves 
were affected neither by the cells' attachment status nor 
by these point mutations. 
The cytoskeletal protein paxillin is normally phosphory- 
lated on tyrosine in response to cell a~dhesion, possibly by 
FAK  (Schaller and Parsons,  1995).  Suspended cells that 
expressed the wild-type CD2-FAK had hyperphosphory- 
luted paxillin (Fig. 2, top) compared with those that ex- 
pressed the CD2-FAK mutants. This result and the high 
phosphorylation level indicate that CD2-FAK has consti- 
tutive signaling activity in the MDCK cells. 
FAK that is phosphorylated on tyrosine 397 complexes 
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calization of  CD2-FAK in MDCK  cells. 
The  CD2-FAK  (wild-type),  CD2-FAK 
(397* or 454"), or CD2 plasmids (Chan et 
al., 1994) were cotransfected with a  plas- 
mid bearing the neomycin phosphotrans- 
ferase gene into a homogeneous subclone 
of MDCK  or  HaCat  cells. The  Western 
blot probed with anti-CD2 (A, left)  con- 
firms  expression  of  the  ~175-kD  CD2- 
FAK or ~50-kD CD2 proteins, while the 
blot probed  with anti-FAK antibody (A, 
right) shows the relative expression levels 
of endogenous FAK  (closed  arrow)  and 
CD2-FAK  (open  arrow)  proteins.  (B) 
CD2-FAK  localizes  to  focal  contacts. 
Control MDCK cells  (b),  control HaCat 
cells  (d),  or  their  respective  CD2-FAK- 
expressing derivatives (a and c) were fixed 
and  stained  with  anti-CD2  antibody. 
(Cells  expressing  the  CD2  ectodomain 
alone showed weak  diffuse staining over 
the  entire cell  surface;  data  not shown). 
Because  focal  contacts  were  not readily 
detectable  in  MDCK  cells,  constructs 
were  expressed  transiently in REF-52 fi- 
broblasts. After transfection with the CD2 
ectodomain (e), CD2-FAK (wild-type) 0'), 
or  CD2-FAK (397*)  (g)  expression con- 
structs, the cells were fixed and stained for 
CD2 (e-g) or vinculin (h). 
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forms of CD2-FAK, endogenous FAK, and paxillin in suspended 
and adherent MDCK cell variants;  in vivo association  of CD2- 
FAK (wild-type) with c-src. Lysates prepared from suspended  (S) 
or adherent (A) MDCK cells expressing CD2-FAK (wild-type), 
CD2-FAK(454*),  or CD2-FAK(397*)  were immunoprecipitated 
with anti-CD2, anti-FAK, anti-paxillin, or anti-src antibodies.  Top 
left: anti  phosphotyrosine  immunoblot  of the  immunoprecipi- 
tates;  top right: the same blot stripped and reprobed with anti- 
CD2,  anti-FAK, and  anti-paxillin  antibodies  to  confirm equal 
loading. Bottom left: anti-CD2  immunoblot of anti-src immuno- 
precipitates;  bottom right: the same blot stripped and reprobed 
with anti-src antibodies. 
Figure 3.  CD2-FAK accelerates the spreading of MDCK cells on 
collagen.  2  ×  106  MDCK  (control),  CD2-FAK  (wild-type)/ 
MDCK, or CD2-FAK (397*)/MDCK  cells were plated on col- 
lagen-coated,  BSA-blocked  coverslips  in  serum-free  medium 
containing 0.5 mg/ml BSA. After 8 min at 37°C, unattached cells 
were washed off, and the attached cells were photographed at the 
indicated times. Spread and unspread cells were scored by exami- 
nation of the photographs (~400 total cells per time point) and 
the fractions of unspread cells were plotted as a function of time. 
--l-, control; ---IF-,  CD2-FAK;  .4i-, CD2-FAK(397*). 
in vivo with c-src or the src-related kinase, c-fyn (Cobb et 
al.,  1994;  Schlaepfer et al.,  1994).  To test whether  CD2- 
FAK was capable of this interaction, proteins from CD2- 
FAK/MDCK cells were immunoprecipitated with anti-src 
antibodies and the immunoprecipitates were analyzed for 
the presence of CD2-FAK on Western blots (Fig. 2, bot- 
tom). CD2-FAK (wild-type) coprecipitated with c-src and 
this  association was insensitive  to the  adhesion status of 
the cells. By contrast, CD2-FAK (397* or 454*) failed to 
associate with c-src. The combined results suggested that 
CD2-FAK localizes normally in attached cells, but is ac- 
tive in both suspended and attached cells. 
The MDCK cells that expressed CD2-FAK were found 
to spread on collagen-coated glass faster than control cells 
or cells expressing  CD2-FAK  (397*)  (Fig.  3).  This indi- 
cates that  the  activation of FAK accelerated the  normal 
cellular response to matrix adhesion, and is consistent with 
the reported deficiency of cell spreading in FAK knockout 
cells (Ilic et al., 1995). Despite these effects, the morphol- 
ogy of the cells was not discernibly affected by CD2-FAK 
(data not shown). 
CD2-FAK Confers Anoikis Resistance 
MDCK cell lines that stably expressed the constructs de- 
scribed above were assayed for anoikis by the criteria of 
internucleosomal  DNA  cleavage  and  subgenomic  DNA 
content in flow cytometric analyses. A large fraction (21.2%) 
of the cells expressing the unfused CD2 ectodomain alone 
underwent apoptosis when detached from matrix (Fig. 4). 
These results were similar to those reported previously for 
untransfected MDCK cells (Frisch and Francis, 1994). In 
contrast,  MDCK  cells  expressing  CD2-FAK  (wild-type) 
showed N10-fold less  apoptosis than  the  other transfec- 
tants.  Cells expressing either  the  kinase  domain  or SH2 
target domain ihutants of CD2oFAK remained fully sensi- 
tive to anoikis, demonstrating the dependence of anoikis 
rescue upon these activities of FAK. CD2-FAK similarly 
rendered  HaCat cells anoikis resistant,  showing that  the 
effect occurs in at least two different epithelial cell types. 
The expression of a  CD8-FAK fusion protein in MDCK 
cells conferred  anoikis resistance  as  well,  ruling  out  the 
Figure 4.  CD2-FAK and CD8-FAK confer anoikis resistance  in 
MDCK cells. Agarose gel analysis of low-mol-wt DNA extracted 
from the  indicated  cell  lines  held  in  suspension  (normalized 
against total cellular protein) and the corresponding percentages 
of cells undergoing  apoptosis,  determined by flow cytometry (as 
described in Materials  and Methods) are shown. 
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MDCK Cells 
Cell line  Soft agar plating efficiency (%) 
CD2  0 
CD2-FAK (397*) clone 4  0 
CD2-FAK (397*) clone 10  0 
CD2-FAK (wild-type) clone 9  "12.8 ±  1.2 
CD2-FAK (wild-type) clone 30  12.5 ±  1.2 
bcl2/mdck clone 21  9.5 ±  1.6 
bcl2/mdck clone 32  7.1.±  1.3 
src/mdck  18.8 +- 3.4 
ras/mdck  0.8** ±  0 
3  ×  104 cells of the indicated cell lines were plated on soft agar as described previ- 
ously (Frisch,  1991) incubated for 16 d and photopgraphed;  colonies greater than eight 
cells were counted on duplicate plates and averaged. 
(NB: each colony was ~10-fold larger compared with the other cell lines). 
possibility of spurious  signaling  effects due to the  CD2 
ectodomain. 
These results  suggested  that FAK plays an important 
role in integrin-mediated control of cell survival and that 
the adhesion-independent activation of FAK can bypass 
this  control.  Moreover, the  point  mutants  suggest  that 
FAK  kinase  activity and  interactions with  SH2  domain 
proteins, such as src-family proteins, are both required for 
this effect. 
CD2-FAK Confers Anchorage Independence and 
Tumorigenicity upon MDCK Cells. 
To test whether the activated FAK would allow cells to 
grow independently of anchorage, soft agar colony assays 
were performed (Table I). CD2-FAK (wild-type), but not 
CD2-FAK (397*), endowed MDCK cells with anchorage 
independence. However, the HaCat keratinocytes, which 
normally  undergo  both  terminal  differentiation  (Breit- 
kreutz et al., 1993) and apoptosis in suspension, did not be- 
come anchorage independent; this implies that CD2-FAK 
may  affect anoikis  but  not  terminal  differentiation,  al- 
though the latter has not been tested directly. 
CD2-FAK-expressing  cells  were  also  tumorigenic  in 
nude mice (100% tumor incidence; Table II), although the 
CD2-FAK/MDCK cells produced smaller tumors (41.0 mg 
+/-  16) than did v-Ha-ras-transformed MDCK cells (270 
mg +/-  150). The CD2-FAK (397*)-expressing cells were 
nontumorigenic. 
CD2-FAK Controls Anoikis But Not Growth 
Factor Responsiveness 
To assess the role of apoptosis in the oncogenic potential 
of the CD2-FAK-expressing cells, MDCK cells that over- 
expressed the bcl-2 protein--and were therefore resistant 
to anoikis (Frisch and Francis, 1994)--were tested for an- 
chorage-independent growth  (Table I)  and  tumorigenic 
potential  (Table  II).  Surprisingly,  the  bcl-2-transfected 
cells scored positively in both assays. This result suggested 
that the acquisition of anoikis resistance was sufficient to 
confer the transformed phenotype in MDCK cells. 
To investigate whether CD2-FAK affected growth fac- 
tor pathways, we first examined MAPK activity. MAPK is 
stimulated  by  cell  adhesion  in  fibroblasts  in  a  process 
thought  to involve FAK  (Schlaepfer et  al.,  1994).  As  a 
Table II. CD2-FAK Confers Tumorigenicity in MDCK Cells 
Incubation  Tumor 
Cell line  Cell number  time  Incidence 
days 
CD2-FAK (397*) clone 4  5  ×  106  56  0/8 
CD2-FAK (397*) clone 10  5  ×  106  56  0/8 
CD2-FAK (wild-type) clone 9  5  ×  106  56  8/8 
CD2-FAK (wild-type) clone 30  5  X  l06  56  8/8 
ras/mdck  1 >(  106  30  8/8 
bcl2/mdck clone 21  5  ×  106  56  8/8 
Cells in 0.3 ml of serum-free  medium were injected at two sites per mouse into four 
female, 4--5-wk-old,  nu/nu mice (Harlau Sprague-Dawley). Tumors were dissected 
and weighed after the incubation times indicated. 
control, we first studied the effect of cell adhesion to col- 
lagen on MAP kinase activity in rat embryonic fibroblast 
REF-52 cells. Activation of MAP kinase enzymatic activ- 
ity was studied by an immunocomplex kinase assay using 
myelin basin  protein  (MBP)  as  a  substrate.  Consistent 
with the  results reported by others  (Chen et  al.,  1994), 
MAP kinase activity was transiently increased in REF-52 
cells plated on an ECM substratum (Fig. 5). The maximal 
activity of MAP kinases, four to fivefold induction (nor- 
malized to the amount of MAPK) compared to detached 
cells, was seen at 15-30 min after plating, whereafter the 
kinase activity declined. When cells were kept in suspen- 
sion, MAP kinase activity remained unchanged relative to 
constitutively growing controls (not shown).  In contrast 
00t 
100 
0  20  40  60  80  1  O0  120 
Time (rain) 
Figure  5.  CD2-FAK  does  not  augment  adhesion-stimulated 
MAP kinase activity. Serum-starved  REF-52 cells (filled boxes), 
CD2-FAK/MDCK  cells (filled circles), and MDCK ceils (open 
circles) detached from plastic were replated on collagen for 15, 
30, 60 or 120 min. Whole cell lysates (200 Ixg total protein) were 
subjected to MAP kinase immunocornplex assays using MBP as a 
substrate; phosphorylated MBP was separated by a 15% SDS gel 
and autoradiographed.  MAP kinase activity is expressed as arbi- 
trary units based on the quantitative  analysis of the MBP bands 
by phosphorlmager.  -II--,  REF-52;  -0--,  CD2-FAK/MDCK; 
--O--, MDCK. 
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Maximal fold  Percent of maximum in  Percent of maximum in 
Cell line  increase  0.5% serum  0.2% serum 
Control  29.8  9.1  ±  3  3.2 ±  1 
CD2-FAK wtc 9  25.3  6.8 ±  2  3.0 +- 0 
CD2-FAK wtc 30  23.1  10.3 ±  3  5.2 -+  1 
src/mdck  17.1  61.4 ±  6  45.6 +  9 
Ceils (5 ×  104) were plated in 35-mm diameter wells and changed to medium contain- 
ing the indica~d content of FBS after 6 h. Cells were counted in triplicate at time zero, 
at 6 h postplating (time zero) and 96 h postplating. The maximal fold increases in cell 
number occurred in 10% serum. 
with the results we obtained with fibroblasts, MAP kinase 
activity was only slightly stimulated (1.2-fold) by adhesion 
in normal MDCK cells and in CD2-FAK--expressing cells; 
no quantitative  or qualitative differences were found in 
the  MAP  kinase  activation  between  the  CD2-FAK- 
expressing and parental MDCK cells (Fig. 5). By contrast, 
the MAPK activity of MDCK cells was highly stimulated 
by PMA. These results argue against a mechanism wherein 
CD2-FAK transformed MDCK ceils by activating the ras- 
MAPK pathway. 
Second, FAK complexes with c-src and could potentially 
activate it (Cobb et al., 1994). However, total cellular c-src 
kinase  activity was  not affected by CD2-FAK  (data  not 
shown). 
Finally, because it was still possible that novel targeting 
of c-src or other molecules might stimulate growth factor 
responsiveness in the CD2-FAK-expressing cell lines, the 
cell's dependence on serum concentration for growth was 
measured. Serum dependence was greatly reduced by the 
expression of v-src, but  was  not  affected by CD2-FAK 
(Table III). 
Discussion 
In this report, we have shown that the activation of an in- 
tegrin signal transducer, FAK, confers resistance to anoikis. 
In the case of MDCK cells, this was accompanied by an- 
chorage-independent growth  and significant tumorigenic 
potential. 
Analogous to previous studies with such molecules as 
raf-1 kinase (Stokoe et al., 1994) and sos (Aronheim et al., 
1994), the membrane targeting of FAK via either CD2 or 
CD8  served to  activate  it,  by mechanisms  that  are  not 
clear. Speculatively, the targeting may alleviate FAK's 
requirement for upstream activating signals,  such as the 
proposed  interaction  of  FAK  with  integrin  13-subunits 
(Schaller et al., 1995). The possibility that CD2-FAK's ef- 
fects might arise from spurious protein interactions rather 
than  the preservation of FAK in an active state in sus- 
pended cells was  considered; it was  unlikely for several 
reasons.  First,  the  CD2-FAK  protein  localized  to  focal 
contacts, suggesting that its carboxy-terminal focal adhe- 
sion targeting sequence (FAT; Hildebrand et al.,  1993) is 
functional and that the CD2 transmembrane domain does 
not drive it to specific sites on the membrane. Second, the 
kinase and SH2 target sequences of the FAK moiety were 
required for the observed effects. Third, the substitution 
of CD2 extracellular and  transmembrane  domains  with 
those  of CD8  was  without consequence.  Finally,  CD2- 
FAK stimulated  cell spreading,  an  activity attributed  to 
normal FAK (Ilic et al.,  1995);  artifactual interactions of 
CD2-FAK with novel cellular substrates would be difficult 
to reconcile with this effect. In recent complementary ex- 
periments, the perturbation of FAK in vivo using inhibi- 
tory peptides or antibodies was found to cause apoptosis 
(Hungerford, J., M.  Compton, M. Matter, B. Hoffstrom, 
and C. Otey, manuscript submitted for publication). While 
this supports our conclusions, the interference with FAK 
causes cell rounding, which might suffice to cause apopto- 
sis, confounding the interpretation. 
The results reported herein suggest that FAK may con- 
tribute  to  epithelial  carcinogenesis.  In  this  connection, 
FAK is often overexpressed human carcinomas (Owens 
et al., 1995). However, the role of FAK in transformation 
is  apparently unusual for a  signal transducer: FAK con- 
trois anoikis without detectably altering growth factor re- 
sponse  pathways.  This conclusion was  obtained through 
the use of a cell line (MDCK) in which the alleviation of 
anoikis sufficed to produce anchorage-independent growth, 
and in turn, tumor formation in vivo. That MDCK cells 
had this property was supported by results with bcl-2 ex- 
pression. Bcl-2 is an  apoptosis suppressor that is appar- 
ently devoid of growth-stimulatory effects and in fact in- 
hibits the growth of several tumor cell lines (Pietenpol et al., 
1994). We reported previously that bcl-2 conferred anoikis 
resistance in MDCK cells (Frisch and Francis, 1994). Sur- 
prisingly,  we  found  herein  that  bcl-2  also  transformed 
MDCK cells, demonstrating that the conversion of MDCK 
cells  to  an  anoikis-resistant  state  suffices  to  transform 
them. 
That the effect of CD2-FAK was primarily on anoikis 
rather than growth control was also supported by several 
revealing differences between cells transformed by CD2- 
FAK and those transformed by ras or src. First, in contrast 
with CD2-FAK, activated ras or v-src caused a  dramatic 
relief of growth factor dependence and an increased maxi- 
mal proliferation rate. Second, transformation by ras  or 
src inhibited MDCK cell spreading on collagen (data not 
shown), while CD2-FAK stimulated it. Third, CD2-FAK 
expression neither morphologically transforms nor confers 
anchorage-independent  growth  in  NIH3T3  fibroblasts 
(Schwartz, M., Scripps Research Institute, personal com- 
munication),  a  cell  type  that  is  normally  resistant  to 
anoikis but can be transformed by oncogenes that stimu- 
late mitogenesis, such as ras. Finally, although cell adhe- 
sion transiently stimulates  the  (mitogenic) MAPK path- 
way  in  fibroblasts,  we  observed no  such  stimulation  in 
MDCK cells. The basis for this discrepancy is unclear, but 
it  may be  that  MAPK  is  stimulated  by focal  adhesion 
plaque formation or stress fiber formation, which are more 
extensive in fibroblasts than in epithelial cells, rather than 
by integrin-matrix interactions alone. In this connection, 
cytochalasin treatment prevents adhesion-dependent MAPK 
activation in fibroblasts (Chert et al., 1994). 
In summary, the acquisition of resistance to anoikis is a 
potentially crucial step in the acquisition of a fully trans- 
formed phenotype by epithelial cells. Certain cells (such as 
MDCK)  appear to fall short of the transformed state by 
this step alone, but it can be transgressed by the activation 
of FAK, or, potentially, other integrin signal transducers. 
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